Epizyme, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Collaboration revenue
Revenue
Collaboration Revenue
Total revenue
Operating expenses:
Cost of revenue
Research and development
Selling, general and administrative
Total operating expenses
Operating loss
Other (expense) income, net:
Interest (expense) income, net
Other expense, net
Change in fair value of warrants to purchase common stock
Related party non-cash interest expense related to sale of future royalties
Other (expense) income, net
Loss before income taxes
Income tax provision
Net loss
Accretion of convertible preferred stock
Net loss attributable to common stockholders
Net loss per share attributable to common stockholders:
Basic
Diluted
Weighted-average common shares outstanding used in net loss per share attributable to common stockholders:
Basic
Diluted
Other comprehensive (loss) income:
Unrealized gain (loss) on available for sale securities
Comprehensive loss

Comments